

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: E. Raspe et al.

GAU: 1656

SERIAL NO: 09/646,924

EXAMINER: S. Chunduru

FILING DATE: September 25, 2000

FOR: USE OF ROR RECEPTORS FOR SCREENING SUBSTANCES USEFUL FOR THE TREATMENT OF
ATHEROSCLEROSIS

AMENDMENT TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

14/D
AF/NEE. Williams
10-9-02

SIR:

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required.☐ Applicant(s) is/are entitled to small entity status.☒ Additional documents filed herewith: Article: "Determinants of Target Gene Specificity for ROR α 1: Monomeric DNA Binding by an Orphan Nuclear Receptor"

The fee has been calculated below:

CLAIMS	CLAIMS REMAINING		HIGHEST NO. PREVIOUSLY PAID FOR	NO. OF EXTRA CLAIMS	RATE		CALCULATIONS
TOTAL	22	MINUS	22	0	x	\$18 =	\$0.00
INDEPENDENT	5	MINUS	5	0	x	\$84 =	\$0.00
	<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS						
	TOTAL OF ABOVE CALCULATIONS						\$0.00
	<input type="checkbox"/>						
	<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY						\$0.00
	<input type="checkbox"/> RECORDATION OF ASSIGNMENT				+	\$40 =	\$0.00
	TOTAL						\$0.00

☐ A check in the amount of \$_____ is attached.☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. § 1.136, and any additional fees required under 37 C.F.R. § 1.36 for any necessary extension of time may be charged to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Robert E. McCarthy, Registration No. 46,044
Agent for ApplicantsMILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410
Date: October 1, 2002O.K. to enter
Spec
2-7-03



RECEIVED

OCT 03 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

re application of : Box: AF
E. Raspe et al. : Examiner: S. Chunduru
Serial No.: 09/646,924 : Group Art Unit: 1656
Filed: September 25, 2000 :

For: **USE OF ROR RECEPTORS FOR SCREENING SUBSTANCES USEFUL
FOR THE TREATMENT OF ATHEROSCLEROSIS**

AMENDMENT UNDER 37 C.F.R. §1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action of July 1, 2002, please amend the above-identified application and consider the remarks as follows:

IN THE CLAIMS:

Please cancel claims 2 and 13 without prejudice or disclaimer.

Please **amend** claims 1, 3-9, 16 and 22 as follows:

1. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction comprising contacting said substance with a ROR α receptor, or a response element thereof involved in the regulation of the apo C-III gene, and measuring the level of apo C-III gene expression.

3. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction, comprising contacting said substance with (a) a ROR α receptor involved in the regulation of the expression of the apo C-III gene, (b) a response element of a ROR α receptor, or (c) a nuclear factor which functionally couples ROR α to a RNA polymerase complex, and then measuring: